Theranica’s migraine DTx receives FDA clearance for adolescent use

mobihealthnews, 25/01/2021

Partagé par : 

Beesens TEAM

Theranica’s migraine DTx receives FDA clearance for adolescent use

"Nerivio is a wireless, noninvasive remote electrical-stimulation wearable that is worn on the upper arm at the onset of a migraine.
Theranica, an Israeli prescription digital therapeutics developer for migraine and other pain conditions, has received 510(k) clearance from the U.S. Food and Drug Administration for its Nerivio device.

The device has been cleared for acute treatment of episodic or chronic migraine in people 12 years and older.

Nerivio is a wireless, noninvasive remote electrical-stimulation wearable that is worn on the upper arm at the onset of a migraine. Each treatment session is 45 minutes long and uses remote electrical neuromodulation to activate the brain's native conditioned pain modulation mechanism to treat pain and associated migraine symptoms..." Lire la suite